02552

2.0150.98%
WR

William Robert Keller

Independent Non-Executive Director

Mr. William Robert Keller is Independent Director of Gland Pharma Limited from June 15, 2026. Mr. Keller has been Independent Non-Executive Director of Hua Medicine (Shanghai) Ltd. since September 14, 2018. He serves as Independent Director at Artisan Acquisition Corp. He is an experienced professional in the pharmaceuticals industry. Mr. Keller joined Roche Group in Basel in 1972 and served from 1990 to 2003 in several marketing and General Manager positions at Roche Group in South America and Asia. He has also served as the Chairman and Honorary Chairman of Rdpac (Research based foreign Pharmaceutical Association China). Mr. Keller served as Director at Cathay Industrial Biotech, Ltd. (formerly known as Cathay Biotech Inc.) until August 18, 2025. Mr. Keller was Chairman of Coland Holdings Limited since December 05, 2010 until December 2020. Mr. Keller is primarily responsible for supervising and providing independent judgment to the Board of. Since May 2017, Mr. Keller has been an Independent Non Executive Director of WuXi Biologics (Cayman) Inc. since May 17, 2017. Since 2010, he holds directorship at Coland Pharmaceutical Co., Ltd. He served as the Chairman of Coland Pharmaceutical Co., Ltd. until November 2020. From September 2014 to December 2015, Mr. Keller served as an independent director of WuXi PharmaTech (Cayman) Inc, a biopharmaceutical Between 1974 to 2003, Mr. Keller served in various positions at the Roche Group, including as the general manager of Roche China Ltd. He was Vice President of Roche Brazil Ltd., General Manager of Roche Colombia Ltd. He was general manager of Shanghai Roche Pharmaceutical Ltd. He has been a vice chairman of the Shanghai Association of Enterprises with Foreign Investment, a senior consultant to the Shanghai Foreign Investment Development Board and the deputy general manager of Zhangjiang Biotech and Pharmaceutical Base Development Co., Ltd. Mr. Keller previously held directorships in biopharmaceutical companies including Alexion Pharmaceuticals, Inc., a company listed on NASDAQ ( Stock code: ALXN) from December 2009 to May 2015. He is a Founder at Keller Pharma Consultancy in 2003. he successfully oversaw and established Roche in China since 1990 until 2003. He is an independent director at China Nuokang Bio Pharmaceutical Inc. and Fosun Pharmaceutical Co. ltd and a supervisor and board member of TaiGen Biopharmaceuticals Holding Limited. He served in several marketing and General Manager positions at Roche Group in South America and Asia until 2003. He has also served as the Chairman of HBM Biomed China Partners, a company listed on NASDAQ (stock code: ALXN) from December 2009 to May 2015, China Nuokang Pharmaceutical Inc. a company listed on NASDAQ (stock code: NKBP) from August 2008 to December 2011. He was Independent Non executive Director of Hua Ling Medicine Limited. He is an Independent Director of Cathay Biotech since September 2014. Mr. Keller obtained a Bachelor of Science degree from the School of Economics and Business Administration in Switzerland in July 1972.

Positions